Panitumumab outcome by tumour location analysis
PRIME study: baseline characteristics
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and
poster).
WT
RAS
Panitumumab + FOLFOX
FOLFOX
Left
(n = 169)
Right
(n = 39)
Left
(n = 159)
Right
(n = 49)
ECOG PS, %
0
1
2
62.7
33.1
4.1
56.4
38.5
5.1
55.3
38.4
5.7
55.1
38.8
6.1
Prior adjuvant, %
No
Yes
82.8
17.2
74.4
25.6
83.6
16.4
79.6
20.4
BRAF
status, %
Mutant
Wild type
Failure
4.1
92.3
3.6
33.3
66.7
0
5.0
93.1
1.9
32.7
65.3
2.0
Metastatic sites, %
Liver + other
Liver only
Other only
70.4
19.5
10.1
53.8
15.4
30.8
67.9
19.5
12.6
71.4
10.2
18.4
Median age, years
61
62
62
61
